Kombucha for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Kombucha for Health & Longevity

Created on 09/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Fermented sweet tea: organic acids, tea compounds, live microbes, a little sugar, caffeine and trace alcohol. Clearest benefit is lower blood sugar in type 2 diabetes; where blood sugar is already normal the picture reverses. Harms are better documented than benefits: acid load, tooth enamel wear, alcohol that outruns its label. (Full Review)

Protocol

Standard daily dose
200–250 mL once daily
Trials used this range for 8–10 weeks; the only dose with controlled human data.
Best time of day
With the largest carbohydrate meal
The post-meal glucose effect requires co-ingestion; intake within six hours of bedtime is avoided (10–25 mg caffeine per 250 mL).
Single versus split dosing
Single dose with the main meal
Matches every trial protocol. Two 100 mL servings suit reflux or bloating, at double the daily enamel exposure.
Time to effect
Fasting glucose
4 weeks
Fasting glucose shifts took four weeks; a fair trial needs at least two months.
Post-meal glucose
First serving
Post-meal glucose changes appear with the first serving.
Blood lipids
10 weeks
Lipid changes took ten weeks; microbiota six to eight weeks.

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Immunocompromise (CD4 below 200 cells/µL, cytotoxic chemotherapy, neutrophils below 1.0 × 10⁹/L, solid-organ transplant on immunosuppression)
  • Chronic kidney disease stage 4 or 5 (eGFR below 30 mL/min/1.73 m²)
  • Decompensated liver disease (Child-Pugh B or C), or prior supplement-associated liver injury
  • Active or recent alcohol use disorder, or court- or employer-mandated alcohol testing
  • Erosive esophagitis (Los Angeles Grade C or D)
  • Diagnosed histamine intolerance or mast cell activation syndrome
  • Children under four years; untreated advanced dental erosion
  • Disulfiram, metronidazole and cefotetan (unpasteurised product)
  • Calcineurin inhibitors and other immunosuppressants (tacrolimus, ciclosporin, mycophenolate), unpasteurised product
Key Interactions
  • Lactate-raising drugs (metformin, linezolid, stavudine)
  • Insulin and insulin secretagogues (glipizide, glyburide, repaglinide)
  • Warfarin
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine)
  • Over-the-counter acid suppressants (omeprazole, esomeprazole, famotidine, calcium carbonate antacids)
  • Over-the-counter analgesics (ibuprofen, naproxen, high-dose acetaminophen)
  • Iron, zinc and calcium supplements
  • Supplements with additive glucose-lowering effects (berberine, cinnamon extract, chromium picolinate, alpha-lipoic acid)
  • Green tea extract and other high-catechin supplements
  • Prolonged fasting, ketogenic diets and alcohol-monitoring programmes
    •

Risk & Side Effects

  • Medium: Increased fasting insulin and insulin resistance in healthy adults
  • Low: Severe metabolic and lactic acidosis; acute liver injury; lead poisoning from reactive brewing vessels; invasive infection in immunocompromised people; unintended alcohol intake
  • Speculative: Dental enamel erosion; histamine and biogenic amine reactions; digestive discomfort and bloating

Monitoring

Marker Target Why
Fasting glucose 75–86 mg/dL The endpoint kombucha moved in diabetes trials
HbA1c 4.8–5.3% Confirms whether short-term glucose change persists
Fasting insulin 2–5 µIU/mL Detects the insulin-resistance signal seen in healthy drinkers
ALT 10–26 U/L (men), 10–19 U/L (women) Screens for the liver injury reported in case series
High-sensitivity C-reactive protein Under 0.5 mg/L Tracks the inflammation endpoint used in kombucha trials
Serum bicarbonate with anion gap Bicarbonate 24–28 mmol/L; anion gap 8–12 mmol/L Detects the acid load behind the reported acidosis cases
Triglycerides Under 80 mg/dL Lipid endpoint that moved in two trials
Ferritin 40–70 ng/mL (women), 50–120 ng/mL (men) Tea polyphenols reduce plant-iron absorption
Blood lead Under 1.0 µg/dL Detects leaching from glazed ceramic or crystal vessels

Cadence: Baseline, then metabolic and liver markers at 4–6 weeks, 12 weeks, and every 6–12 months if intake continues.

Qualitative Assessment

  • Stool frequency and Bristol stool scale form, recorded daily for the first two weeks
  • Bloating, reflux and post-meal fullness, since these are the usual reasons people abandon a trial
  • Energy stability across the afternoon, the most commonly reported subjective change
  • Sleep onset latency and night waking, to catch the small caffeine contribution
  • Tooth sensitivity to cold, an early indicator of enamel wear
  • Skin flushing, headache or hives within an hour of drinking, which suggest histamine intolerance
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.